Literature DB >> 8260709

Heterogeneous expression of a novel MPC-1 antigen on myeloma cells: possible involvement of MPC-1 antigen in the adhesion of mature myeloma cells to bone marrow stromal cells.

N Huang1, M M Kawano, H Harada, Y Harada, A Sakai, A Kuramoto, O Niwa.   

Abstract

Recent immunophenotypic analysis has shown that the heterogeneous expression of the adhesion molecule VLA-5 classifies myeloma cells into VLA-5+ mature and VLA-5- immature subpopulations. To further clarify the two myeloma subpopulations, we generated a monoclonal antibody, MPC-1, by immunizing mice with an adherent human myeloma cell line, KMS-5. The MPC-1 antibody recognized a 48-Kd surface antigen on KMS-5 but not on U-266, a nonadherent human myeloma cell line. Specificity characterization showed that MPC-1 antigen was expressed on mature myeloma cells, normal plasma cells, and mature B cells, whereas pre-B cells and germinal center B cells lacked its expression. Monocytes and a human bone marrow stromal cell line, KM102, also expressed this antigen. Two subclones of MPC-1+ VLA-5+ (KMS-5Ad) and MPC-1-VLA-5+ (KMS-5NAd) were separated from the KMS-5 cell line. The KMS-5NAd adhered to KM102 more tightly than did the KMS-5NAd, and the U-266 (MPC-1-VLA-5-) displayed almost no adherence to the KM102. The adhesion of the KMS-5Ad was partially inhibited by the MPC-1 antibody. These results, taken together, suggest that the MPC-1 antigen serves as a differentiation marker for B-lineage cells, including plasma cells, and may function as an adhesion molecule involved in the interaction of mature myeloma cells with bone marrow stromal cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8260709

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells.

Authors:  H K Müller-Hermelink; A Greiner
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

2.  Growth mechanism of human myeloma cells by interleukin-6.

Authors:  Michio M Kawano; Hideaki Ishikawa; Naohiro Tsuyama; Saeid Abroun; Shangqin Liu; Fu-Jun Li; Ken-ichiro Otsuyama; Xu Zheng
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  An increase in MPC-1- and MPC-1-CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005).

Authors:  Ken-ichiro Otsuyama; Hideki Asaoku; Michio M Kawano
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

4.  The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents.

Authors:  Yoshiaki Kuroda; Akira Sakai; Yoshiko Okikawa; Shoso Munemasa; Yuta Katayama; Hideo Hyodo; Jun Imagawa; Yasuo Takimoto; Hajime Okita; Megu Ohtaki; Akiro Kimura
Journal:  Int J Hematol       Date:  2005-05       Impact factor: 2.490

5.  Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1.

Authors:  Teresa S Hawley; Irene Riz; Wenjing Yang; Yoshiyuki Wakabayashi; Louis Depalma; Young-Tae Chang; Weiqun Peng; Jun Zhu; Robert G Hawley
Journal:  Am J Hematol       Date:  2013-03-08       Impact factor: 10.047

6.  Establishment of a monoclonal antibody to human myeloma cell: relation to chemotherapy and extramedullar infiltration.

Authors:  N Kuribayashi; H Hata; H Matsuzaki; M Yoshida; T Sonoki; A Nagasaki; T Kimura; N Harada; K Takatsuki
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

Review 7.  Homing behaviour of the malignant cell clone in multiple myeloma.

Authors:  I Van Riet; K Vanderkerken; C de Greef; B Van Camp
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

8.  Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells.

Authors:  Yoshiko Okikawa; Akira Sakai; Yasuo Takimoto; Masaaki Noda; Jun Imagawa; Yuta Katayama; Yoshiaki Kuroda; Hajime Okita; Kingo Fujimura; Akiro Kimura
Journal:  Int J Hematol       Date:  2004-05       Impact factor: 2.490

Review 9.  Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules.

Authors:  Hideaki Ishikawa; Naohiro Tsuyama; Michio M Kawano
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

10.  IL-6-induced activation of MYC is responsible for the down-regulation of CD33 expression in CD33+ myeloma cells.

Authors:  Karim Shamsasenjan; Ken-Ichiro Otsuyama; Saeid Abroun; Mohd S Iqbal; Maged S Mahmoud; Hideki Asaoku; Michio M Kawano
Journal:  Int J Hematol       Date:  2009-03-04       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.